From Wikipedia, the free encyclopedia
Chemical compound
ABT-436 is an
orally active , highly
selective
vasopressin
V1B receptor
antagonist which was under development by
Abbott Laboratories and
AbbVie for the treatment of
major depressive disorder ,
anxiety disorders , and
alcoholism but was discontinued.
[1]
[2]
[3] It reached
phase II
clinical trials prior to the discontinuation of its development.
[1]
[3]
See also
References
^
a
b
"ABT 436" . AdisInsight . Springer Nature Switzerland AG.
^ Wernet W, Hornberger WB, Unger LV, Meyer AH, Netz PA, Oost T, et al. (2008). In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558 . Proceedings of Society for Neuroscience. Washington DC, USA. p. Abstract 560.
^
a
b Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, et al. (April 2017).
"A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence" . Neuropsychopharmacology . 42 (5): 1012–1023.
doi :
10.1038/npp.2016.214 .
PMC
5506792 .
PMID
27658483 .